The vitamin D analogue KH1060 and the retinoids all-trans retinoic acid (ATRA), 9-cis-retinoic acid (9-cRA) and 4-hydroxyphenyl retinamide (4-HPR) induce differentiation and/or apoptosis and inhibit clonal growth of acute promyelocytic leukaemia cells. We have studied the effects of these agents in vitro on cells from 12 patients with other forms of acute myeloblastic leukaemia (AML). Treatment with KH1060 (10 + cells, measured by CD11b/7-AAD double staining, was increased in 6/6 cases treated with KH1060 or the combination of 9-cRA and KH 1060, and in 5/6 cases treated with 9-cRA. No overall significant change in bcl-2 or bax expression on G0/G1 cells was found after 3 days' suspension culture with the analogues. However bcl-x was downregulated in G0/G1 cells treated with KH1060 (median bcl-x relative fluorescence intensity = 45.3 in cells treated with KH1060, compared with 65.7 in control wells, P = 0.028). We conclude that CD34 + samples are relatively resistant to the growth inhibition induced by KH1060 and 9-cRA. However, downregulation of bcl-x in cells which have survived treatment with KH1060 may increase the susceptibility of the remaining leukaemic cells to cytotoxic drugs.
Introduction
Normal haemopoiesis involves complex interactions between molecules regulating proliferation, differentiation and apoptosis. The concept that the balance between regulatory molecules can be pharmacologically manipulated in order to promote the differentiation and apoptosis of malignantly transformed haemopoietic cells has been a major focus of research for 20 years. 1, 2 Vitamin A metabolites and vitamin D have a role in normal haemopoietic differentiation 3, 4 and are thus good candidates for the induction of differentiation in leukaemia. The vitamin A metabolite all-trans retinoic acid (ATRA) is used to treat patients with acute promyelocytic leukemia (APL). 5 APL is characterised by translocations of the gene which codes for the retinoic acid receptor RAR␣. Ligation of this receptor is known to induce differentiation in leukemic cell lines. 6 In combination with other agents ATRA has also been found to inhibit the growth of non-APL (non-M3) AML blasts in vitro. 7, 8 A number of retinoid and vitamin D analogues have been synthesized in recent years in the search for compounds which target malignant cell differentiation and apoptosis with minimal toxic effects on other systems. Several of these show promise in vitro in their effects on leukaemic cell lines or APL cells. The vitamin D analogue KH1060 inhibits the growth of HL60, NB4 and U937 cells. 6,9-11 9-cis-retinoic acid (9cRA), a stereoisomer of ATRA, inhibits clonal growth in leukaemic cell lines and primary AML cells. 9, [11] [12] [13] N-(4-hydroxyphenyl) retinamide (4HPR) induces apoptosis in leukaemic cell lines, including ATRA-resistant lines.
14, 15 The combination of KH1060 and 9cRA proved more active in inducing differentiation and apoptosis and suppressing the colony growth of HL60 and NB4 cells than either agent alone. 9, 11 We therefore investigated whether this combination, as well as the agents used singly, would have an effect on primary AML cells.
Several oligonucleotide blocking or transfection studies have proved that regulation of the anti-apoptotic molecule bcl-2 in leukaemic cells can control cellular susceptibility to apoptosis, including the apoptosis induced by cytotoxic drugs. [16] [17] [18] [19] Bcl-2 is downregulated in leukaemic cells treated with differentiating agents, 6, 9, 11, [20] [21] [22] [23] and this mechanism may underlie the increased sensitivity of leukaemic cells to the combination of cytotoxic drugs and ATRA. 17 In this study, we have therefore investigated the expression of bcl-2, and also bcl-x and bax, in AML cells treated with KH1060 and 9 cRA.
Materials and methods

Primary cell suspension culture
Fresh or thawed cells from 12 patients with non-M3 AML were studied. Eleven samples were taken at presentation, one at relapse (Table 1 ). All samples consisted of Ͼ90% malignant cells and were also CD2-depleted with Dynabeads (Dynal UK Ltd, Merseyside, UK). Cells were set up in suspension culture in sterile Falcon tubes at 10 6 cells/ml with RPMI 1640, 10% FCS, 2 mM L-glutamine, 100 U/ml IL3, 100 U/ml GM-CSF and 25 ng/ml G-CSF (the latter kindly donated by Amgen, Cambridge, UK), and with penicillin and streptomycin (Sigma, Poole, UK). Our choice of cytokines was designed to optimise the survival of colony-forming units, and was based on the report of Van der Lely and colleagues. 24 Two control tubes were cultured without further agents; 10 −6 M ATRA (Sigma), 
Flow cytometric analysis of cell number, viability and differentiation
Cells were harvested after 6-7 days. EDTA was added to cultured cells at a final concentration of 5 mM. The tubes were then incubated for 15 min at 37°C to loosen adherent cells. After thorough mixing, 145 l aliquots were removed and incubated for 10 min at room temperature with 5 l phycoerythrin-conjugated antibody to the differentiation marker CD11b (leu 15; Becton Dickinson, Cowley, UK) or isotype matched control. 50 l of 60 g/ml 7-amino-actinomycin D (7AAD) dissolved in PBS was then added. This dye detects dead or apoptotic cells without the need for permeabilisation. 25 Cells were incubated at room temperature with 7AAD for 20 min. For cell counting, aliquots of fixed normal mononuclear cells which had been stained with CD45FITC (Becton Dickinson) were used. When these cells are mixed with the cultured cells of interest, two clear populations -the FITCnegative cultured cells and FITC-positive fixed normal cellscan be distinguished (see Figure 1) . Fixed, stained, normal cells were diluted to 3 × 10 5 /ml and 100 l aliquots were added to the control tubes. 26 Cells were mixed well and analysed (without any rinsing) on a Becton Dickinson FACScan with Cellquest software. Figure 1 illustrates the analysis and gating format which allows the absolute number, viability and CD11b status of the cultured cells to be quantified.
Semi-solid assay for residual clonogenic cells
Following the removal of cell aliquots from the suspension culture for flow cytometry, the remaining cells were rinsed twice in sterile PBS with 1% BSA and resuspended in 500 l 0.9% methyl cellulose with RPMI, 10% FCS, 2 mM L-glutamine, Hepes buffer, penicillin and streptomycin, 100 U/ml IL3, 100 U/ml GM-CSF and 25 ng/ml G-CSF. After thorough mixing, 100 l aliquots were pipetted in triplicate into 96-well plates and cultured for up to 2 weeks. Colonies of at least 20 cells were counted.
CD34 measurement
CD34 was measured using FITC-labelled Birma K3 antibody (Dako, High Wycombe, UK). The number of positive cells was calculated by setting a marker on the plot for isotype and concentration matched control such that 1% of the events fell into the positive sector.
Bcl-2, bax and bcl-x measurement
Bcl-2, bax and bcl-x expression were measured on the cultured cells of the seven patients for whom there were sufficient cells. Thawed cells were CD2-depleted and grown for 3 days with KH1060 or 9-cis-retinoic acid in suspension culture as described above. Cells were then harvested, fixed and permeabilised in 35% ethanol for 10 min, rinsed twice in PBS containing 1% bovine serum albumin and 0.1% sodium azide (PBSAA) and resuspended in the same buffer. Aliquots were then stained with unconjugated antibodies to bcl-x (S-18) or bax (both from Santa Cruz Biotechnology, Santa Cruz, CA, USA), or with appropriate controls as previously described 27 using a FITC-labelled secondary antibody. Bcl-2 was measured using a FITC-conjugated antibody (Dako). After rinsing cells were resuspended in 10 g/ml 7AAD.
Flow cytometry
Fluorescence was measured using a FACScan (Becton Dickinson) with Cellquest software.
Data analysis
All our yield, colony and differentiation data are expressed as the finding from the well or tube cultured with retinoid or KH1060 expressed as a percentage of the finding from the well or tube cultured without agent.
Statistics
Friedman's analysis of variance was used to analyse differences between groups, followed by Wilcoxon's signed rank tests where appropriate.
Results
Effect of the analogues on the viable cell yield
KH1060, 9-cRA and 4-HPR can all induce apoptosis in leukaemic cell lines. We measured the number of viable cells remaining in AML patient samples after 6-7 days' suspension culture. A flow cytometric method was used, incorporating the nuclear dye 7-AAD which is taken up by apoptotic cells and gives unambiguous results on a large number of cells, and is therefore more reliable than conventional trypan blue exclusion (see Figure 1 for details). There was considerable variation in responses as shown in Table 2 . Overall, a signifi-
Figure 1
Simultaneous analysis of cell number, viability and differentiation.
Step 1: Using control tube (leukaemia cells + fixed, CD45-stained normal mononuclear cells of known concentration + IgG2a PE control + 7AAD), region 1 is set on a FSC/SSC plot to exclude doublets and debris (not shown) and is used to gate all subsequent analysis. Step 2: region 2 (plot 1) is set on fixed, CD45-FITC stained (FL1 high) cells.
Step 3: region 3 (plot 1) is set on leukaemic cells (which are not stained with CD45 and are therefore FL1 low).
Step 4: the ratio of leukaemic cells to fixed, CD45-stained normal mononuclear cells is calculated (R3:R2). The number of leukaemic events can now be calculated from the predetermined concentration of the fixed, stained cells.
Step 5: using the second tube (leukaemia cells + CD11bPE + 7AAD), region 4 (plot 2) is set on 7AADlow/FSChigh events, ie viable leukaemic cells.
Step 6: the number of viable leukaemic cells is calculated. This is equal to the total number of leukaemic events from step 4 × R4/R1. Step 7: (plot 3) using the control tube the PE control fluorescence (FL2) is plotted against 7-AAD (FL3) and region 5 is set around viable cells.
Step 8: (plot 4) using the second tube, region 6 is set around the CD11b PE fluorescence.
Step 9: the proportion of viable, differentiated cells, R6/(R5+R6), is calculated.
Table 2
Effects of retinoids and KH1060 on patient cell viability after 6-7 days incubation MJ  84  95  100  16  56  PS  29  82  63  123  128  DS  100  14  79  50  7  DC  111  85  97  25  67  RF  80  78  71  54  71  JS  87  86  97  35  39  JR  125  112  61  59  67  MM  93  1  121  44  7  IS  83  89  64  10  39  JF  123  99  153  145  185  DI  133  128  120  18  104  Median  93  86  97  44 
The effects of the analogues on clonal cell growth
Following suspension culture, cells were rinsed thoroughly and resuspended in semi-solid medium to establish whether they were capable of clonal growth once the analogues had been removed. In 3/12 samples, no colonies grew, even in the control wells, in which cells were cultured in the absence of any analogues (Table 3 ). For the remaining nine samples, a statistically significant decrease in growth was noted with 9-cRA (median growth compared with control colonies = 73%, P = 0.01), KH1060 (median = 5%, P = 0.03) and both agents combined (median 37%, P = 0.02). Colony growth was suppressed in 8/9 cases by KH1060, but increased in one case (RF) accounting for the smaller statistical significance compared with 9-cRA. Further inhibition of clonal growth by the combination of 5 × 10 −7 M 9-cRA and 5 × 10 −7 M KH1060 was only noted in one culture (JS) when compared to 10 −6 M KH1060 alone, and the combination was equally efficient to KH1060 alone in one culture and less efficient in six cultures (Table 3 ). 4-HPR had no overall effect on clonal growth (median = 100% of control colonies, not significant). The significant growth inhibitory effect of 9-cRA showed it to be more effective than the same concentration of ATRA (median 79%, not significant).
Patient CD34 status and colony growth
We have previously shown that ATRA induces bcl-2 downregulation in CD34-negative but not in CD34-positive AML samples. 23 We therefore hypothesised that CD34-positive cells may be less susceptible to apoptosis induced by retinoids and vitamin D compounds. The CD34 status of the cases ana- Table 3 Effects DI  125  93  125  25  135  JS  83  97  93  54  18  IS  68  73  100  2  44  FS  79  66  108  5  11  DC  70  64  95  47  45  RF  106  100  115  143  94  JF  311  81  166  0  37  JR  51  12  24  0  2  MJ  29  16 lysed with respect to their cellular response to 9-cRA and KH1060 is shown in Table 4 . Six cases were CD34 negative (Ͻ10% CD34 + cells in sample), six were CD34 positive. Following primary suspension cultures, cells from all six CD34-positive samples grew in control semi-solid cultures, whereas cells from 3/6 CD34-negative cultures failed to proliferate. 10 −6 M KH1060 completely abolished colony growth in all three CD34-negative samples and 10 −6 M 9-cRA inhibited the number of colonies to 11, 16 and 81% of control values. In the six CD34-positive samples median colony growth was inhibited to 36% of control values by KH1060 and to 83% of control values by 9-cRA. Despite the low number of CD34-negative samples which were clonogenic in control cultures, the differential effect of KH1060 was so marked as to be statistically significant when Fisher's exact test was applied to dichotomised results. This test showed significant growth inhibition (P = 0.01) by KH1060 in CD34-negative compared to CD34-positive samples.
Effect of the analogues on leukaemic cell differentiation
Patient cells were harvested after 6-7 days in suspension culture with and without the analogues KH1060, 9-cRA and 4-HPR. CD11b expression was then measured as an indicator of differentiation. Patients were divided into two categories: those with initially primitive blast cells (FAB types M0, M1, M2) and patients whose blasts were already more differentiated (FAB types M4, M5, M6). In the former group KH1060 and the combination of KH1060 and 9-cRA induced differentiation in all six samples (Table 5 and Figure 2 ). 9-cRA induced differentiation in 5/6 samples, and the one (M1/M2) sample which failed to show an increase was one in which control cells themselves underwent spontaneous differentiation in culture.
CD11b expression did not show such a marked increase in M4, M5 and M6 clones (Table 5) , which was unsurprising, considering their initially more mature status. However, dual staining with 7AAD and CD11b enabled us to address the question of whether there is a discernible link between differ- 
Figure 2
Histograms illustrating increased CD11b expression in treated cells from M0/M1 patient DI (upper plot) and M1 patient FS (lower plot). entiation and apoptosis in these samples on treatment with the analogues. If differentiation is coupled to apoptosis, we would expect to see an increase in the ratio of apoptotic to viable CD11b + cells. In the six cases with a more mature phenotype (one M4, four M5, one M6), the ratio of apoptotic to viable CD11b + cells was increased in all samples treated with KH1060 or the combination KH1060 + 9-cRA, and in 5/6 treated with 9-cRA ( Figure 3 and Table 5 ). No marked changes were noted in cells treated with 4-HPR. (The immature clones were not included in this analysis since the lower numbers of differentiated cells made the interpretation of flow cytometric data unreliable.) Table 5 Effects of KH1060 and retinoids on differentiation ATRA, 10 
Bcl-x, bax and bcl-2 expression
Alterations in bcl family expression were measured by twocolour flow cytometry using 7-AAD to distinguish the viable G0/G1 subpopulations of cells stained with antibodies to bcl-2, bax and bcl-x (Figure 4) . We studied samples from the seven patients for whom sufficient cells were available; five were CD34 positive and two CD34 negative. Using ANOVA and Wilcoxon signed rank tests, no significant change in bcl-2 or bax expression was found after 3 days' suspension culture with the analogues. However a statistically significant downregulation of bcl-x was noted on cells treated with KH1060 (P = 0.028) ( Figure 5 ). The median bcl-x relative fluorescence intensity was 45.3 in cells treated with KH1060, compared with 65.7 in control wells. We have previously shown by Western blotting that the bcl-x expressed in AML samples consists entirely of the long, 31 kDa anti-apoptotic form, 27 therefore a decrease in bcl-x L expression in these cells may favour apoptosis.
Discussion
Leukaemic cell growth can be inhibited by induction of differentiation or through apoptosis of clonogenic progenitor cells. Retinoid and vitamin D pathways can be linked to both differentiation and apoptosis and are therefore potentially attractive for the treatment of acute myeloid leukaemia, as exemplified by the use of ATRA in the treatment of APL. In this study we examined the effects of the retinoids 9-cRA and 4-HPR and the vitamin D analogue KH1060 on the clonogenic growth of AML cells following primary suspension culture, as well as the yield and differentiation of cells in primary culture. We found that only KH1060 significantly suppressed growth in primary suspension culture across the broad range of leukaemic clones. However, we found that samples treated with 9-cRA, as well as those treated with KH1060, were significantly less clonogenic than control samples, implying that 9-cRA induces a change in these cells which impairs their ability to proliferate rather than directly inducing apoptosis. The combination of 9-cRA and KH1060 also inhibited clonogenic growth, but at a dose of 5 × 10 −7 M of each analogue, this was less effective than 10 −6 M KH1060 alone. We had chosen to investigate the combination of 9-cRA with KH1060 since synergistic growth inhibition had been found in APL cells. 11 However, in non-M3 AML cells we did not observe consistent complementary effects for the two compounds. The inhibitory effect of 9-cRA alone on the growth of non-M3 AML cells has been described by others 13 and our findings are consistent with theirs.
We have previously shown that AML samples which downregulate bcl-2 in response to ATRA in vitro are CD34-negative. 23 This is important, as it gives rise to the suspicion that ATRA therapy, whilst reducing the overall number of blast cells, may fail to affect (CD34 + ) leukaemic progenitors. In the current study we have compared the effect of the retinoids and of KH1060 on CD34-positive and CD34-negative AML cases. We found that neither compound could completely eradicate clonal growth in CD34-positive samples. However only one case (RF, with relapsed erythroleukaemia) was completely refractory to the inhibitory effects of KH1060: some clonal inhibition occurred in the remaining 5/6 CD34 + cases and it will therefore be interesting to test the sensitivity of CD34
+ leukaemic samples to combinations of vitamin D analogues and cytotoxic drugs.
In normal haemopoiesis, early progenitor cells tend to express more anti-apototic proteins (eg bcl-2, bcl-x L ) and less pro-apoptotic proteins (eg fas) than their more differentiated offspring, and are less likely to undergo apoptosis. The link between induction of differentiation and induction of apoptosis has been extensively studied in the leukaemic cell line HL60. Mutation studies have shown that retinoid ligation of the receptor termed RAR induces differentiation, whereas ligation of the RXR is required to inhibit growth.
6,28 9-cRA has high affinity for both receptors. 12 In leukaemic cells RXR also forms heterodimers with the vitamin D receptor (VDR). 29 VDR ligation induces CD11b expression in U937 cells. 30 Specific effects of KH1060 in VDR pathways are not yet characterised. Comparing the retinoids with KH1060, we found that KH1060 had a greater effect on clonogenic growth and a lesser effect on differentiation induction, and in contrast, these findings were reversed for 9-cRA. These findings may in part be explained by the differential effects on RAR, RXR and VDR activation. We have illustrated that flow cytometry is a useful tool for elucidating whether differentiation and apoptosis are linked events in cells stimulated by vitamin A or D compounds: our results on 7AAD/CD11b double labelling of myelomonoblastic patient cells indicate that KH 1060 and 9-cRA induce apoptosis in cells expressing CD11b.
The downregulation of bcl-2 in retinoid and vitamin Dinduced differentiation and apoptosis is well characterised. 6, 9, 11, [20] [21] [22] However, one drug resistant HL60 subline underwent differentiation without loss of bcl-2 protein 31 and transfection of bcl-2 does not inhibit differentiation. 19 Using flow cytometric protein measurement in conjunction with cell cycle analysis, we were able to examine protein expression on G0/G1 cells, thus ruling out the generalised protein loss of cell decay. We did not find significant downregulation of bcl-2 in our patient samples. This is unsurprising in the light of our previous finding that ATRA failed to downregulate bcl-2 in CD34
+ cases. 23 The role of other bcl-2 family proteins in vitamin A-and D-induced differentiation and apoptosis is less Bcl-x expression in permeabilised cells treated with 7AAD, showing the R4 gate set around G0/G1 cells (patient MJ). Sub G0 (R3) cells express less bcl-x and their exclusion allows a truer picture of bcl-x expression in viable cells than could be obtained from a bulk cell analysis.
Figure 5
Flow cytometric quantitation of bcl-x expression in untreated cells and cells treated with KH1060. Note that bcl-x is expressed on a log scale since values span a 2-3 log range. Values are linearised logarithmic channel numbers for G0/G1 bcl-x fluorescence after subtracting isotype control fluorescence.
well characterised. The pro-apoptotic protein bax is reported to be upregulated in NB4 cells cultured with KH1060 and 9cRA, 11 but there are contradictory reports of its effects on HL60 cells during differentiation. 9, 21 In these studies we did not note any significant change in bax expression. The antiapoptotic bcl-x L is downregulated in normal CD34
+ and in ATRA-treated HL60 cells differentiating towards granulocytes 32 and in leukemic cell lines differentiating towards erythrocytes. 33 Bcl-2 and bcl-x are controlled by distinct, 34 as well as common 35 pathways. High bcl-x L expression is associated with drug resistance [36] [37] [38] and therefore reducing bcl-x L may be a useful mechanism for increasing AML blast sensitivity to drug-induced apoptosis. The downregulation of bcl-x noted in our study is likely to involve pathways used in normal haemopoietic differentiation and to be one of a number of mechanisms through which differentiated cells become more sensitive to pro-apoptotic stimuli.
Thus, although the block on normal differentiation is a defining characteristic of AML, we conclude that the retinoid 9-cis retinoic acid and the vitamin D analogue KH1060 induce certain characteristics of increased differentiation in non-M3 leukaemic clones, and that the subsequent growth of these clones, especially with KH1060, is significantly impaired. Furthermore KH1060 clearly induces apoptosis in these cases, and, by downregulating bcl-x, may be of value in overcoming resistance to cytotoxic chemotherapy in AML.
